Developer docs
API playgroundTry for free, no card

Search company profiles

Trigone Pharma

Full company profile

uuid02lqs6z

Namestring
Trigone Pharma
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Trigone Pharma is a privately held, for-profit biotechnology company founded in 2020 and headquartered in Ra'anana, Israel. According to the firmographic record, the company develops intravesical sustained-release therapies intended for bladder diseases and urological cancers. This positioning indicates a localized, prolonged-exposure drug-delivery platform rather than a systemic-therapy approach, targeting organ-confined urological indications. The current headcount of 1–10 employees is consistent with an early, preclinical-to-early-clinical stage of development.

The company's underlying technology, pipeline, and business model cannot be characterized in detail from the available data. No products, pricing models, distribution channels, customer segments, partnerships, awards, patents, or trademarks are disclosed. The company website (https://www.trigonepharma.com) currently serves only a verification/loading page with no substantive content. There is no documented management team, no funding history, no M&A or strategic transaction activity, and no regulatory milestones in the supplied record, leaving commercialization mechanics, capital structure, and pipeline depth unsubstantiated by the available evidence.

Short descriptiontext

Trigone Pharma is an early-stage Israeli biotech developing intravesical sustained-release drug therapies for patients with bladder diseases and urological cancers.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRa'anana, Israel
HQ citystring
Ra'anana
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
intravesical drug delivery, bladder disease therapeutics, urological cancer treatment, sustained-release pharmaceuticals, urology drug development
Industry2 codes
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Urological Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Trigone Pharma develops intravesical sustained-release therapies for bladder diseases and urological cancers. The company focuses on drug delivery approaches that administer therapeutics directly into the bladder and release them over extended periods to treat urological conditions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Intravesical sustained-release therapies
CategoryUrological Therapeutics
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AbbVie acquired TARIS Biomedical and is a major oncology/urology incumbent. Its ownership of TARIS's intravesical sustained-release platform makes it both a direct technology owner and a likely strategic acquirer of complementary assets like Trigone.

TypeBroad incumbent
Description

Ferring is a specialty pharma with deep urology/uro-oncology presence, including bladder cancer therapies. Its focus on urological specialty products makes it a natural strategic acquirer for a sustained-release intravesical developer like Trigone.

TypeEmerging player
Description

enGene is developing intravesical gene therapies (EG-70) for non-muscle invasive bladder cancer. While its modality is gene therapy rather than small-molecule sustained release, it competes in the same intravesical NMIBC treatment paradigm.

4Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS markets Opdivo for urothelial carcinoma and is a major oncology incumbent. Its established bladder cancer franchise and immuno-oncology pipeline make it a relevant comparator and potential strategic acquirer in the space.

TypeDirect peer
Description

UroGen Pharma develops intravesical therapies for urological cancers, most notably Jelmyto (mitomycin) for low-grade upper tract urothelial cancer. It is the most direct public comparable to Trigone's intravesical sustained-release focus on bladder and urological cancers.

TypeEmerging player
Description

Photocure specializes in bladder cancer diagnostics (Hexvix/Cysview) used during TURBT procedures. While focused on detection rather than sustained-release treatment, it is a focused urology-oncology company serving the same bladder cancer care pathway.

TypeBroad incumbent
Description

Merck's Keytruda is approved for NMIBC and other urothelial cancers, making it the dominant large-cap incumbent in bladder cancer immunotherapy and a likely strategic comparator for any novel intravesical therapy.

TypeDirect peer
Description

TARIS Biomedical developed intravesical sustained-release drug-device systems for bladder cancer and was acquired by AbbVie. Its lead program TAR-200 (gemcitabine) directly parallels Trigone's sustained-release intravesical approach for urological cancers.

TypeBroad incumbent
Description

Astellas markets Padcev and has a significant oncology/urology franchise including bladder cancer products. As a large incumbent in urological oncology, it represents both a potential acquirer and competitor for Trigone's targeted indications.

10Lipomedix Pharmaceuticals
TypeEmerging player
Description

Lipomedix developed intravesical therapies for NMIBC, including a thermosensitive liposomal formulation. As a small specialty developer of intravesical bladder cancer therapies, it is a closely comparable emerging peer to Trigone.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trigone Pharma

Urological Therapeuticstrigonepharma.com

Trigone Pharma is an early-stage Israeli biotech developing intravesical sustained-release drug therapies for patients with bladder diseases and urological cancers.

What Trigone Pharma does

Trigone Pharma is a privately held, for-profit biotechnology company founded in 2020 and headquartered in Ra'anana, Israel. According to the firmographic record, the company develops intravesical sustained-release therapies intended for bladder diseases and urological cancers. This positioning indicates a localized, prolonged-exposure drug-delivery platform rather than a systemic-therapy approach, targeting organ-confined urological indications. The current headcount of 1–10 employees is consistent with an early, preclinical-to-early-clinical stage of development.

The company's underlying technology, pipeline, and business model cannot be characterized in detail from the available data. No products, pricing models, distribution channels, customer segments, partnerships, awards, patents, or trademarks are disclosed. The company website (https://www.trigonepharma.com) currently serves only a verification/loading page with no substantive content. There is no documented management team, no funding history, no M&A or strategic transaction activity, and no regulatory milestones in the supplied record, leaving commercialization mechanics, capital structure, and pipeline depth unsubstantiated by the available evidence.

Trigone Pharma firmographics

Firmographics
Name
Trigone Pharma
Website
https://trigonepharma.com
Company type
Private
Founded year
2020
Headcount range
1–10 employees
Short description
Trigone Pharma is an early-stage Israeli biotech developing intravesical sustained-release drug therapies for patients with bladder diseases and urological cancers.
Ownership category
akta.pro rank

Trigone Pharma industry classification

Industry
Product category
Urological Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Intravesical drug delivery
  • Bladder disease therapeutics
  • Urological cancer treatment
  • Sustained-release pharmaceuticals
  • Urology drug development

Where Trigone Pharma is headquartered

Location

Headquarters

HQ city
Ra'anana
HQ country
Israel
HQ region
Middle East

Markets served

Trigone Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Trigone Pharma product offering

Product offering

Core offering

Trigone Pharma develops intravesical sustained-release therapies for bladder diseases and urological cancers. The company focuses on drug delivery approaches that administer therapeutics directly into the bladder and release them over extended periods to treat urological conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Intravesical sustained-release therapies

Companies that use Trigone Pharma

Customer profile

Ideal customer profiles1 record

Trigone Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Trigone Pharma partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights2 records

Trigone Pharma competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: AbbVie acquired TARIS Biomedical and is a major oncology/urology incumbent. Its ownership of TARIS's intravesical sustained-release platform makes it both a direct technology owner and a likely strategic acquirer of complementary assets like Trigone.
  • Ferring Pharmaceuticals: Ferring is a specialty pharma with deep urology/uro-oncology presence, including bladder cancer therapies. Its focus on urological specialty products makes it a natural strategic acquirer for a sustained-release intravesical developer like Trigone.
  • Bristol-Myers Squibb: BMS markets Opdivo for urothelial carcinoma and is a major oncology incumbent. Its established bladder cancer franchise and immuno-oncology pipeline make it a relevant comparator and potential strategic acquirer in the space.
  • Merck & Co. Merck's Keytruda is approved for NMIBC and other urothelial cancers, making it the dominant large-cap incumbent in bladder cancer immunotherapy and a likely strategic comparator for any novel intravesical therapy.
  • Astellas Pharma: Astellas markets Padcev and has a significant oncology/urology franchise including bladder cancer products. As a large incumbent in urological oncology, it represents both a potential acquirer and competitor for Trigone's targeted indications.

Emerging players

  • enGene: enGene is developing intravesical gene therapies (EG-70) for non-muscle invasive bladder cancer. While its modality is gene therapy rather than small-molecule sustained release, it competes in the same intravesical NMIBC treatment paradigm.
  • Photocure ASA: Photocure specializes in bladder cancer diagnostics (Hexvix/Cysview) used during TURBT procedures. While focused on detection rather than sustained-release treatment, it is a focused urology-oncology company serving the same bladder cancer care pathway.
  • Lipomedix Pharmaceuticals: Lipomedix developed intravesical therapies for NMIBC, including a thermosensitive liposomal formulation. As a small specialty developer of intravesical bladder cancer therapies, it is a closely comparable emerging peer to Trigone.

Direct peers

  • UroGen Pharma: UroGen Pharma develops intravesical therapies for urological cancers, most notably Jelmyto (mitomycin) for low-grade upper tract urothelial cancer. It is the most direct public comparable to Trigone's intravesical sustained-release focus on bladder and urological cancers.
  • TARIS Biomedical: TARIS Biomedical developed intravesical sustained-release drug-device systems for bladder cancer and was acquired by AbbVie. Its lead program TAR-200 (gemcitabine) directly parallels Trigone's sustained-release intravesical approach for urological cancers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Trigone Pharma social profiles

Digital presence

Trigone Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trigone Pharma leadership team

Management profile

Number of profiles

Trigone Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trigone Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trigone Pharma

What does Trigone Pharma do?

Trigone Pharma develops intravesical sustained-release therapies for bladder diseases and urological cancers. The company focuses on drug delivery approaches that administer therapeutics directly into the bladder and release them over extended periods to treat urological conditions.

When was Trigone Pharma founded?

Trigone Pharma was founded in 2020. It employs 1 to 10 people.

Where is Trigone Pharma based?

Trigone Pharma is headquartered in Ra'anana, Israel, in the Middle East region.

Who are Trigone Pharma's main competitors?

Broad incumbents on record are AbbVie, Ferring Pharmaceuticals, Bristol-Myers Squibb, Merck & Co. and Astellas Pharma. Emerging players are enGene, Photocure ASA and Lipomedix Pharmaceuticals. Direct peers are UroGen Pharma and TARIS Biomedical.

Does Trigone Pharma have an API?

No public API is recorded for Trigone Pharma.

What industry is Trigone Pharma in?

Trigone Pharma's product category is Urological Therapeutics. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals